Gene Therapy & Editing
Gene therapy and editing is a densely interconnected field built on CRISPR nucleases, base and prime editing, and AAV vector platforms. Value is shared through a web of cross-licences, pharma collaborations and equity stakes, and nearly every platform company names several direct rivals. The dossier shows large partners validating the platforms through collaborations and equity, alongside heavy customer concentration, partner exits, government march-in rights, supply-chain and tariff exposure, and safety-driven regulatory actions. Recent activity points to strategic retrenchment away from allogeneic CAR-T and toward in vivo editing, with several near-term clinical and regulatory readouts pending.
Active institutional funds added a net $1.4 billion in Q2 2026, versus $2.6 billion in Q1 2026 — an inflow 46% smaller. 70% of companies in this sub-theme saw increased active positions in Q2 2026.
Overview
Gene Therapy & Editing covers companies that treat genetic disease either by editing DNA (CRISPR-Cas nucleases, base editing, prime editing, and older meganuclease, TALEN and zinc-finger approaches) or by delivering functional genes through viral vectors, chiefly AAV. The field has two structural layers. The first is foundational intellectual property that is licensed, sublicensed and cross-licensed among participants. Examples are CRISPR Therapeutics and Editas licensing CRISPR/Cas9 rights to Vertex, Editas licensing base-editing rights to Beam, Beam and Prime Medicine cross-licensing prime and base editing, Caribou licensing Cas9 technology to Intellia, Precision BioSciences licensing a foundational cell therapy patent family to Caribou, and REGENXBIO licensing its NAV AAV platform to Ultragenyx, Rocket and uniQure. The second layer is therapeutic programmes, which are commercialised alone or through large-pharma partners. Programmes span ex vivo cell therapies, in vivo editing and AAV gene replacement across hemoglobinopathies, ATTR amyloidosis, Duchenne muscular dystrophy, ophthalmology, cardiology, metabolic and rare disease. Many core patents trace to government-funded or university research and carry march-in rights and manufacturing preferences. Participants frequently appear as both licensor and competitor to one another. Development is capital-intensive, so funding typically comes from partner upfronts, milestones and equity investments.
Investment Thesis
Investment thesis details are part of the Pro plan.
Bottleneck Tracker
Bottleneck details are part of the Pro plan.